Literature DB >> 15919281

EuroSCORE predicts long-term mortality after heart valve surgery.

Ioannis K Toumpoulis1, Constantine E Anagnostopoulos, Stavros K Toumpoulis, Joseph J DeRose, Daniel G Swistel.   

Abstract

BACKGROUND: The European System for Cardiac Operative Risk Evaluation (EuroSCORE) is the most rigorously evaluated scoring system in cardiac surgery. We sought to evaluate the performance of EuroSCORE in the prediction of long-term mortality in patients undergoing heart valve surgery.
METHODS: Medical records of patients with isolated or combined heart valve surgery, who were discharged alive (n = 1035), were retrospectively reviewed. Their operative surgical risks were calculated according to EuroSCORE model (standard and logistic). Long-term survival data (mean follow-up 4.5 +/- 3.1 years) were obtained from the National Death Index. Kaplan-Meier curves of the quartiles of standard and logistic EuroSCORE were plotted.
RESULTS: The estimated 5-year survival rates of the quartiles in the standard and logistic EuroSCORE model were: 90.0% +/- 2.3%, 85.1% +/- 2.3%, 64.8% +/- 3.3%, and 55.1% +/- 3.7% (p < 0.0001, log-rank test with adjustment for trend) and 90.4% +/- 2.2%, 86.4% +/- 2.5%, 66.9% +/- 3.3%, and 56.1% +/- 3.3% (p < 0.0001, log-rank test with adjustment for trend) respectively. The odds of death in the highest-risk quartile were 7.46- and 7.82-fold higher than the odds of death in the lowest-risk quartile for standard and logistic EuroSCORE respectively.
CONCLUSIONS: EuroSCORE can be used to predict not only in-hospital mortality, for which it was originally designed, but also long-term mortality in the whole context of heart valve surgery. This outcome can be predicted using the standard EuroSCORE, which is very simple and easy in its calculation.

Entities:  

Mesh:

Year:  2005        PMID: 15919281     DOI: 10.1016/j.athoracsur.2004.12.025

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  External validation of modified EuroSCORE.

Authors:  Fausto Biancari; Jari Laurikka; Jan-Ola Wistbacka; Juha Nissinen; Matti Tarkka
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

2.  Performance of EuroSCORE II compared to EuroSCORE I in predicting operative and mid-term mortality of patients from a single center after combined coronary artery bypass grafting and aortic valve replacement.

Authors:  Kyriakos Spiliopoulos; Vasilis Bagiatis; Oliver Deutsch; Bernhard M Kemkes; Nikolaos Antonopoulos; Dimos Karangelis; Ayman Haschemi; Brigitte Gansera
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-08-29

3.  The revised EuroSCORE II for the prediction of mortality in patients undergoing transcatheter aortic valve implantation.

Authors:  Alexander Sedaghat; Jan-Malte Sinning; Mariuca Vasa-Nicotera; Alexander Ghanem; Christoph Hammerstingl; Eberhard Grube; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2013-07-23       Impact factor: 5.460

4.  EuroSCORE models in a cohort of patients with valvular heart disease and a high prevalence of rheumatic fever submitted to surgical procedures.

Authors:  Ricardo Casalino; Flávio Tarasoutchi; Guilherme Spina; Marcelo Katz; Antonio Bacelar; Roney Sampaio; Otavio T Ranzani; Pablo M Pomerantzeff; Max Grinberg
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

5.  30-day mortality after coronary artery bypass grafting and valve surgery has greatly improved over the last decade, but the 1-year mortality remains constant.

Authors:  Laura Sommer Hansen; Vibeke Elisabeth Hjortdal; Jan Jesper Andreasen; Poul Erik Mortensen; Carl-Johan Jakobsen
Journal:  Ann Card Anaesth       Date:  2015 Apr-Jun

6.  Social deprivation and prognostic benefits of cardiac surgery: observational study of 44 902 patients from five hospitals over 10 years.

Authors:  D Pagano; N Freemantle; B Bridgewater; N Howell; D Ray; M Jackson; B M Fabri; J Au; D Keenan; B Kirkup; B E Keogh
Journal:  BMJ       Date:  2009-04-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.